Atropos Health – a pioneer in evidence-based healthcare known for its Green Button Clinical Informatics Consult Service – recently announced that it has completed strategic financing from Presidio Ventures, which is the venture arm of Sumitomo Corporation Venture Group; Samsung Next, a venture arm of Samsung Electronics; Gaingels; Audere Capital; and others. This funding round enables Atropos Health to accelerate commercial and development opportunities outside the U.S. using its proprietary technology and approach. The initial focus centers on key customers in Japan and Brazil.
The company offers the world’s first award-winning platform for faster data evaluation, evidence generation and Generative AI innovation of research and care. And this platform is designed to meet the demands of health systems and life science companies working to solve increasingly global, diverse, and data-intensive healthcare problems.
The Atropos Evidence Platform is federated, enabling for compliance with sovereign policies on data retention, security, and privacy – such as the General Data Protection Regulation, the standard of EU privacy law. And this critical infrastructure opens up global research opportunities to accelerate evidence generation and representation.
Atropos Health’s cloud-based platform can navigate the data restrictions faced in international markets, providing vital data and insights to frontline physicians and researchers abroad. And this happens at a time when life-saving medical research is increasingly multinational, with over half of all clinical trials taking place outside the US. The diversity in clinical trials is essential to advancing innovation of the best treatments for the right patients. Atropos’ unique global offerings help life science leaders overcome this challenge.
With the funding round and in-market support provided by Presidio and Samsung Next, Atropos Health is commencing engagements with several international customers who will add global RWD to their Atropos Evidence Platform and drive new RWD in the Atropos Evidence Library. And the providers and researchers outside the U.S. can begin to generate evidence-based insights through Atropos Green Button service. Along with the strategic investment, Atropos Health has added partnerships with Analitica, Syndesis Health, DVX, and Project 360 LTD, to provide a critical footprint of in-market data integration support and channel distribution across Asia, South America and the Middle East.
KEY QUOTES:
“While the lack of representation in clinical trials creates an evidence gap for up to 70 percent of U.S patients, this effect is even more pronounced internationally. Lack of representation and relevant evidence on local populations leads to poorly informed treatment decisions and worse outcomes for patients around the world. The support from our new strategic investors, Presidio and Samsung Next, and international healthcare partners underscores the value we deliver on a global scale– to unlock real-world data for evidence-based medicine.”
— Dr. Brigham Hyde, CEO and Co-Founder of Atropos Health
“Our investment in Atropos Health is a testament to our belief that this trailblazing team has the potential to revolutionize how health decisions are made, while saving both time and costs. Atropos Health is on track to make a profound impact on the healthcare industry, and we’re excited to be a part of their journey and look forward to the positive changes they will bring to healthcare worldwide.”
— Rameen Rana, Samsung Next
“The massive proliferation of patient data, coupled with advances in analytical methods, can enable providers and pharmaceutical companies to transform clinical decision-making, optimize drug development, and ultimately improve patient outcomes. We look forward to our strategic collaboration with Atropos Health to support the international expansion of its technology, which we believe will be at the forefront of the healthcare industry’s adoption of evidence-based informatics to enhance therapeutic results and lower the total cost of care.”
— Tyler Schinto, Presidio Ventures
